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The effects of TNF-alpha inhibitor therapy
on the incidence of infection in JIA
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Abstract
Background: Juvenile Idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The
diagnosis is based on the underlying symptoms of arthritis with an exclusion of other diseases Biologic agents are
increasingly used on the side of disease-modifying anti-rheumatic drugs (DMARD) in JIA treatment.
Main body: The aim of this meta-analysis was to investigate the observed infections in JIA children during tumor
necrosis factor (TNF)-alpha inhibitor therapy. A systematic search of three databases (Medline via PubMed, Embase,
Cochrane Library) was carried out up to May 2018. Published trials that evaluated the infectious adverse events in
patients receiving TNF-alpha inhibitor vs. a control group were included in the analysis. Full-text data extraction was
carried out independently by the investigators from ten relevant publications. 1434 patients received TNF-alpha
inhibitor therapy; the control group consisted of 696 subjects. The analysis presented the risk of infection in the
active treatment group (OR = 1.13; 95% CI: 0.76–1.69; p = 0.543). The majority of infections were upper respiratory
tract infections (URTIs). Furthermore, the subgroup analysis demonstrated a higher infection rate in the observed
localization.
Conclusion: Anti-TNF therapy slightly but not significantly increases the incidence of infection in JIA children
compared to other therapies (GRADE: moderate evidence). The most common infections reported were mild URTIs.
Further studies with larger patients number with a strong evidence level are crucially needed to finalize the answer
whether anti-TNF therapy elevates and if yes on what extent the incidence of infection in JIA children.
Trial registration: Prospero: CRD42017067873.
Keywords: DMARD, Infection, JIA, Placebo, TNF-alpha inhibitor
Background
JIA is the most common chronic inflammatory disease
of unknown etiology in childhood. It is a heterogeneous
autoimmune disease, falling into seven categories ac-
cording to the International League of Associations for
Rheumatology (ILAR) classification criteria [1]. This
classification is based on the number of joints affected
during the first six months of the disease and on the
extra-articular involvements. The diagnosis is based on
the clinical manifestations of inflamed joints with an
exclusion of other diseases. Advances in the understand-
ing of immunity and inflammation of the disease have
led to novel therapies for treatment. Patients with JIA,
who had partial response to synthetic DMARDs are
treated with biologic agents, such as anti-TNF agents or
IL-1- or IL-6- antagonists, or T-cell inhibitors [2]. TNF
inhibitors were the first biologic disease-modifying
anti-rheumatic drugs to be used for treating JIA. Two
classes of TNF-alpha blocking agents are currently used
in managing rheumatologic conditions: the monoclonal
anti-TNF antibodies, such as infliximab (INX), adalimu-
mab (ADA), golimumab, and certolizumab pegol, and
the soluble TNF receptor, etanercept (ETA). They are
recommended as second or third-line agents in the poly-
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or oligoarticular forms of JIA, following at least three
months of DMARD therapy [2, 3]. The efficacy of
anti-TNFs has been established in numerous trials.
These drugs have been shown to improve symptoms,
physical functioning, and quality of life [4–7]. Safety
concerns for TNF inhibitors are primarily related to
their immunosuppressive effects. Patients receiving bio-
logics are generally at increased risk of certain viral and
fungal infections, and opportunistic infections, or reacti-
vation of mycobacterial infections [8–11]. In addition to
the immunosuppressive effects of these agents, concomi-
tant use of other immunosuppressive drugs, such as ste-
roids or methotrexate (MTX), and the underlying
inflammatory disease likely contribute to increased in-
fectious risk [12–15]. The primary aim of this
meta-analysis was to explore whether the TNF-alpha in-
hibitor therapy leads to an increased risk of infection in
JIA children.
Main text
To achieve the highest standard for systematic reviews
and meta-analyses, the present study was developed ac-
cording to the recommendations issued for the Preferred
Reporting Items for Systematic Reviews and Meta-Ana-
lyses (PRISMA-P) protocols [16]. (PRISMA checklist.
Additional file 1). RCTs or prospective comparative co-
hort studies were evaluated, the risk of bias and quality
of evidence assessment was conducted using the JADAD
and Newcastle-Ottawa Scale (NOS), and the quality of
evidence was evaluated with the Grading of Recommen-
dations Assessment, Development, and Evaluation
(GRADE) system [17–19].
Literature sources
A systematic search of the literature was carried out up
to May 2018. The search included articles available in
three different databases: in EMBASE, Medline via
PubMed and the Cochrane Library.
Strategy and study selection
Two reviewers manually conducted a comprehensive
search with a combination of the following terms: juven-
ile AND idiopathic AND arthritis OR juvenile AND
rheumatoid AND arthritis (using the old nomenclature)
AND were crossed with etanercept OR adalimumab OR
infliximab OR certolizumab (pegol) OR golimumab or
tumor necrosis factor AND infection. Only English arti-
cles were screened, filters were used, if available, includ-
ing human studies and age (< 18 years). As a result: 196
articles were found in EMBASE, 63 articles in PubMed
and 34 in the Cochrane Library. The titles of and ab-
stracts for the articles identified were assessed by the
two reviewers. Therefore, only those prospective trials
(with or without randomization) comparing infectious
outcomes between a TNF-alpha inhibitor drug and pla-
cebo or DMARD therapy were eligible in the final result.
Poster presentations, conference abstracts, case reports,
retrospective studies and meta-analysis were rejected
from the analysis. Studies using patient years were also
excluded, since the data were impossible to combine sta-
tistically. Patient year expresses the incidents as the total
number of events divided by the total follow up time.
However, the length of exposure to the treatment is
mostly different for different patients, and the patient
year statistic cannot be calculated unless it is reported
specifically. When the appropriateness of an article was
in question, the full-text was evaluated. A third reviewer
was consulted if required for a consensus. Data synthe-
sis. The statistical analysis was conducted with Stata 11
SE (Stata Corp). The number of patients with observed
infection in TNF-alpha inhibitor groups and control
groups was used to calculate the odds ratio (OR). OR > 1
indicates the elevated risk of infection in the TNF-alpha
inhibitor group compared to the control group. It re-
veals significant relationship if both CI > 1. ORs were
pooled using the random effects model with the
DerSimonien-Laird estimator and displayed on forest
plots. To pool the specific infections, the Peto method
was used, as recommended in the Cochrane Handbook
for the meta-analysis of rare events [20]. Summary OR
estimation, p-value and 95% Confidence Interval (CI)
were calculated. P < 0.05 was considered a significant dif-
ference from summary OR = 1. Statistical heterogeneity
was analyzed using the I2 statistic and the chi-square
test to ascertain probability values; p < 0.05 was defined
indicating significant heterogeneity.
Outcome
This meta-analysis investigated prospective trials com-
paring infection risk in JIA children treated with
TNF-alpha inhibitor, in contrast with JIA children re-
ceiving DMARD therapy, or placebo in certain publica-
tions. The studies that were included investigated four
different biologic therapies of currently and previously li-
censed anti-TNF agents: ETA, ADA, INX and golimu-
mab. The primary outcome was the odds of infection in
the TNF-alpha inhibitor group compared to the control
groups.
Results
Search results and study characteristics
Of the 293 publications, ten were eligible for the
meta-analysis. 218 studies were rejected on the basis of
not fulfilling the inclusion criteria (Fig. 1). After dupli-
cates were removed, sixteen articles were retrieved for
more detailed analysis. Of the sixteen studies, further ex-
clusions were made: one was discounted because of lack
of data [21]. Ruperto et al. was rejected due to the
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difference between the follow-up period of the studied
groups [7]. Two articles were excluded owing to the
data only being available in patient years, resulting in
numbers being impossible to combine statistically [6,
22]. One article compared ETA and MTX treatment
with an ETA only cohort. Since both study popula-
tions received anti-TNF therapy, it was not possible
to compare the infectious adverse events [23]. Walters
et al. was excluded due to 18–21 year old patients
participating [24]. Eventually, ten trials proved appro-
priate for the final assessment. Data extraction from
full-length articles was conducted independently by
the two researchers.
No distinction was made between JIA-categories due
to the small number of trials available in the field. Stud-
ies evaluating systemic onset JIA were few [25–27]. The
research mainly consisted of oligo- and polyarticular
forms of JIA. [25–31] Subjects with psoriatic and
enthesitis-related arthritis categories were furthermore
presented in the analysis. [25, 26, 28, 29, 32, 33] In two
studies TNF-alpha inhibitor therapy was initiated be-
cause of active uveitis associated with JIA [28, 34]. Stud-
ies were heterogeneous in the observational period, drug
types, drug dosing, disease activity index, and mean
length of disease at enrolment. In the case of a study
consisting of two parts, e.g. a twelve-week open-label
lead-in phase and a twelve-week double-blind, random-
ized controlled phase, only the latter was included in the
analysis, since the former did not contain a control
group, as discussed above. Table 1 shows the study base-
line characteristics.
Patients
Overall, the study population consisted of 2130 patients.
1434 subjects received at least one dose of TNF-alpha
inhibitor, and 696 patients were selected to receive
DMARD therapy or a placebo as a control group. The
meta-analysis involved those patients who were part the
safety analysis. Therefore, patients withdrawn before the
safety assessment for the study were not included in the
final population of 2130. Within the active agent group,
20 patients were treated with intravenous infliximab, 78
with golimumab, 1245 with subcutaneous ETA and 91
with subcutaneous ADA as a TNF-alpha inhibitor. Con-
comitant drug therapy consisted of DMARDs and
NSAIDs as systemic treatments. Low dose glucocorti-
coids (< 0.2 mg/kg prednisone equivalent or < 10mg/day,
whichever was less) were also permitted. Prior treatment
with biologic was presented in three studies [26, 27, 33].
Control groups
Two types of control groups were used in the studies.
There were seven publications with an RCT design,
six using a placebo [26, 28, 31–34] and one using
DMARD [29] as a control group. However, in every
single placebo-controlled trial, the patients received
concomitant DMARD therapy in both (active and
control) groups, which was MTX [26, 28, 31, 34] or
Fig. 1 Flowchart of the articles included
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Sulphasalazine (SSZ) [33]. One study permitted both
MTX and SSZ (MTX/SSZ) [32]. The other control
group underwent DMARD alone. One RCT [29] and
three prospective cohort studies [25, 27, 30] com-
pared the safety of a TNF antagonist with DMARD
therapy. In the trials, the DMARD therapy involved
either MTX [25, 27, 30] or MTX/SSZ [29].
Risk of bias, and quality of evidence assessment
The JADAD scale was used to evaluate RCTs [17]. All
RCTs were assigned points from one to five for
randomization, blinding procedure and an account of all
patients (Table 1). Each study received at least three
points; no poor-quality articles therefore remained in the
analysis. The JADAD scale is commonly used for evalu-
ating randomized, controlled trials. It is easy to use, reli-
able and valid. The maximum of two points could be
calculated for randomization, also two points for ad-
equate blinding procedure and one extra point for clear
data presentation. In the cases of prospective cohort
studies, the risk of bias was assessed using the
Newcastle-Ottawa Scale (NOS) [18]. Table 1 summarizes
the risk of bias in the non-RCTs as well. The NOS eval-
uates the risk of bias in individual studies throughout
assessing selection, comparability and outcome. For se-
lection a maximum of four points-, for comparability a
maximum two points can be awarded. There are three
items measuring the outcome, therefore a maximum of
three points can be calculated. The more points a study
was collected, the lesser risk of bias it has (Additional
file 2).
The authors estimated the quality of evidence of this
meta-analysis as moderate based on the Grading of Rec-
ommendations, Assessment, Development, and Evalu-
ation (GRADE) system [19]. The GRADE system is a
widely used method to assess the studies that are in-
volved in systematic reviews and meta-analysis. Based
on it, recommendations could be formed. After ranking
and upgrading or downgrading the trials as step one and
two a final grade can be assigned for each outcome. This
can be high, moderate, low or very low grade. In step
four and five a recommendation is to be made. In this
meta-analysis the trials included were RCTs and
well-designed prospective cohort studies with transpar-
ent outcomes and recommendations; the assessment of
individual study validity thus revealed no potential
sources of high risk of bias, based on measurements
using the NOS or JADAD scale.
Outcome: Infectious adverse events
Eight trials reported 218 subjects with an infectious ad-
verse event. Two trials contained no data on the total
number of patients with infections. [28, 33] However,
they included data on subgroups of patients with specific
infections. Consequently, these two studies are only rep-
resented in the subgroup analysis. In the control group,
126 subjects developed some sort of infection. Figure 2
represents the infections developed during the monitor-
ing period. The risk of infection was increased in the
subjects receiving active therapy (OR = 1.13; 95% CI:
0.76–1.69; p = 0.543). A statistically significant risk of in-
fection in the active treatment group was not demon-
strated. Due to the small number of adequate studies in
the field, it was not possible to set up a comparison be-
tween the reported anti-TNF drugs.
Subgroup analysis
The subgroup analysis consists of trials providing data
on different types of infection. The most common in-
fection was upper respiratory tract infection (URTI,
Fig. 3) [26–30, 32, 33]. The risk of URTI is not sig-
nificantly elevated in the active group (OR = 1.10; 95%
CI: 0.65–1.84; p = 0.729). Among those articles with
data on overall infection and URTI together, 23%
URTI was found in the active treatment and 34% in
the control group. Gastrointestinal tract infections
were presented in three studies with an OR of 0.83
(95% CI: 0.29–2.36; p = 0.721) [29, 30, 33]. The statis-
tical analysis also included lower respiratory tract in-
fections [26, 28] (OR = 1.44; 95% CI: 0.39–5.34; p =
0.581), urogenital tract infections [27, 28] (OR = 1.48;
95% CI: 0.48–4.55; p = 0.491), and skin and soft tissue
infections [28, 29] (OR = 1.67; 95% CI: 0.47–5.99; p =
0.429). With an exception of gastrointestinal tract in-
fections, the risk of developing these infections is ele-
vated in patients treated with TNF-alpha inhibitor,
but the relationship is not significant (Fig. 4). There
were less gastrointestinal tract infections observed in
the TNF-alpha inhibitor group. One patient in the ac-
tive treatment group developed septicemia, but no pa-
tient in the control group did so [27]. Severe
opportunistic infections did not present in the popu-
lation under examination. Herpes zoster infections
presented and two cases of localized moniliasis oc-
curred, but no differences were observed between the
groups under investigation (data not presented).
A random effect meta-regression was performed to in-
vestigate the effect of the study length on the association
with an elevated risk of infections; the coefficient and
the corresponding p-value was reported. There is a posi-
tive relationship between the OR and the length of the
study, however it is not statistically significant. (Add-
itional file 3: Figure S1). The small-study effect was
tested with Egger’s test, with p < 0.05 indicating proof of
bias (Additional file 4: Figure S2). A sensitivity analysis
was also carried out omitting one study and calculating
summary OR and 95% CI to investigate the influence of
a single study on the final estimation (Additional file 5:
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Figure S3). The measure of inconsistency between trials
(I2) was 29.2% (p = 0.195), indicating that the studies
were not statistically heterogeneous.
Tuberculosis (TB)
TB-screening is one of the preliminary tests before
the induction of a biologic agent therapy. One trial
that was excluded used a retrospective observational
study design to investigate JIA patients with TB [35].
Latent TB infection prior to therapy was diagnosed
in 3/221 adolescent girls (prevalence rate: 1.4%; 95%
CI: 0.4–4.2). In this meta-analysis there was no
patient diagnosed with TB during the monitoring
period.
Fig. 2 The risk of infection between the TNF-alpha inhibitor and the non-TNF-alpha inhibitor group. The size of the grey marker is proportional to
the weight of the study. (OR = 1.13; 95% CI: 0.76–1.69; p = 0.543)
Fig. 3 Forest plot on the occurrence of upper respiratory tract infection in the TNF-alpha inhibitor group vs. the control group. The risk of URTI is
elevated in the former group (OR = 1.10; 95% CI: 0.65–1.84; p = 0.729)
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Serious infections
In general, the definition of serious infection is an event
that could be life threatening, requiring hospitalization,
need of intravenous treatment, or associated with death.
Adult population studies showed an increased rate of
serious infections associated with TNF-alpha inhibitors
[9, 36]. However, there are few studies investigating
these infections in JIA-patients. The most common ser-
ious infection was pneumonia requiring hospitalization,
with a low number of occurrence (one patient in the
TNF-alpha group, two in the control group). Urosepsis
with unknown pathogen occurred in one patient in the
active treatment group. Therefore, this meta-analysis
showed similar severe infectious events across the two
study groups.
Discussion
To our knowledge, this is the first meta-analysis to investi-
gate the infectious adverse events in JIA children treated
with TNF-alpha inhibitor. Infections are the most frequent
diseases in childhood. The general risk factors for recur-
rent or severe infections could be conditions such as pri-
mary, secondary, or acquired immunodeficiency.
The meta-analysis confirmed that anti-TNF therapy
slightly but not significantly increases the incidence of
overall infection compared to non-biological therapies.
Since the association was not significant, it could be
either a real effect or a coincidence only. The risk of in-
fection appears to be increased in JIA patients as a result
of the disease itself. Generally, patients treated with
TNF-alpha inhibitors are characterized by a longer dis-
ease duration and higher disease activity [15]. Immuno-
suppressive therapies such as anti-rheumatic drugs,
elevate the risk even more [37–39]. Horneff reported a
link between moderate dose of corticosteroid and in-
creased risk of infection [40].
However, the results demonstrated that the most com-
mon infectious events reported in JIA patients were mild
URTIs (23% in the TNF-alpha inhibitor group, 34% in
the control group), which are also widely represented in
the healthy population [41–43].
Additionally, our investigation pointed out that there
was no significant difference between the TNF-alpha in-
hibitor and the control group regarding the incidence of
infection of lower respiratory tract, gastrointestinal tract,
urogenital tract and soft tissue. The incidence of serious
infections is low throughout all clinical trials performed
in JIA patients [15, 40]. Our study was not able to com-
pare the exact incidence of serious infections due to the
incongruent definition across studies and the small
number of patients with severe infections.
In adult population, Askling et al. recognized greater
risk of infection during the first six months of anti-TNF
therapy, with a decrease over time [44]. Time-varying
Fig. 4 Effect of the TNF-alpha inhibitor group vs. the control group on the occurrence of the infectious diseases demonstrated. An increase (with
exception of gastrointestinal tract infections) was observed in the risk of a particular infection in the TNF-alpha inhibitor group
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risk of infection was only reported in one study, there-
fore it could not be statistically analyzed [25]. The mi-
crobiologic results of mild and severe infections in the
patients were limited; most of the studies supplied no in-
formation on the severity of the infections or on the
pathogens involved. Herpes virus was the most com-
monly identified viral pathogen in the articles. Other
than varicella zoster and two cases of moniliasis, oppor-
tunistic pathogens have not been found. Therefore, the
relation between opportunistic infections and TNF an-
tagonists could not be demonstrated in this analysis.
The other main concern with biological treatment is
TB [45, 46]. In this investigation there was no subject di-
agnosed with TB during the study period. Also, the au-
thors would like to emphasize the importance of fungal
infections. The most frequent invasive mycotic agent is
histoplasma. The clinical features are similar to those
which are seen in acute TB. Patients on immunosup-
pressive treatment are at increased risk of developing
disseminated histoplasmosis leading to high rate of
mortality [47–50]. However, there was no data found
regarding histoplasma infections among the reported
articles. In this meta-analysis, relation between ele-
vated risk of TB, histoplasmosis and anti-TNF drugs,
could not be found.
Furthermore, the authors also wish to point out
some important limitations of the study. Experience
from clinical trials investigating paediatric population
are often limited due to low number of patient. The
included trials were clinically heterogeneous in terms
of JIA category, disease duration, previous and con-
comitant drugs used, and infection interpretation. The
papers principally investigated ETA as an active treat-
ment. There were only few studies investigated ADA,
INX or golimumab. Therefore, no comparison was set
up between the TNF-alpha inhibitor drugs.
A major limitation of this meta-analysis is the
meagre evidence published to date. Most of the arti-
cles have short follow-up period, resulting in limited
power to detect rare events. Further studies with
strong evidence and longer monitoring period are
called for examine the pathogens involved in the in-
fections, the precise severity of the infectious diseases
and the localizations as well as to compare the differ-
ent kinds of TNF-alpha inhibitor drugs.
Conclusion
Biologics in combination with other immunosuppressive
agents, such as MTX and corticosteroids, have become
an important component in the effective management of
patients in the pediatric population with a variety of
autoimmune conditions, such as JIA. The benefits of
treatment with biologics in the past two decades out-
weigh the possible risk of infection. This meta-analysis
demonstrates that anti-TNF-alpha therapy slightly but
not significantly increases the incidence of infection
compared to other therapies in JIA children (GRADE,
moderate evidence). The number of serious and oppor-
tunistic infections was low. Data on the long-term safety
of anti-TNFs and other biologics in children and adoles-
cents are still scarce.
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